Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.66 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529262 | 0.86 | CYP19A1 (0.66) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL13524655 | 0.83 | CYP11B2 (0.64) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL13524663 | 0.83 | CYP19A1 (0.62) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1039245 | 0.82 | CYP19A1 (0.67) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL13529265 | 0.81 | CYP19A1 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL3295820 | 0.80 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL25491 | 0.80 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL685516 | 0.80 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| S-Fadrozole SCHEMBL13449014 | 0.80 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1041691 | 0.79 | CYP19A1 (0.59) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | CYP19A1 2832/4885CYP11B2 4426/4885CYP11B1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.